Top

American Journal of Clinical Dermatology

Published in:

Open Access 01-08-2020 | Melanoma | Review Article

Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?

Authors: Patrick Schummer, Bastian Schilling, Anja Gesierich

Published in: American Journal of Clinical Dermatology | Issue 4/2020

Abstract

Approximately 50% of all melanomas harbor an activating BRAF mutation. In patients suffering from an advanced melanoma with such a somatic alteration, combined targeted therapy with a BRAF and MEK inhibitor can be applied to significantly increase the survival probability. Nevertheless, resistance mechanisms, as well as negative predictive biomarkers (elevated lactate dehydrogenase levels, high number of metastatic organ disease sites, brain metastasis), remain a major problem in treating melanoma patients. Recently, a landmark overall survival (OS) rate of 34% after 5 years of combined targeted therapy in treatment-naïve patients was reported. On the other hand, patients harboring a BRAF mutation and receiving first-line immune checkpoint blockade with ipilimumab plus nivolumab showed a 5-year OS rate of 60%. As indicated by these data, long-term survival can be reached in melanoma patients but it remains unclear if this is equivalent to reaching a true cure for metastatic melanoma. In this review, we summarize the recent results for combined targeted therapy and immunotherapy in advanced melanoma harboring an activating BRAF mutation and discuss the impact of baseline characteristics on long-term outcome.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. https://doi.org/10.3322/caac.21551.CrossRefPubMed

Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell. 2012;150(2):251–63. https://doi.org/10.1016/j.cell.2012.06.024.CrossRefPubMedPubMedCentral

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949–54. https://doi.org/10.1038/nature00766.CrossRef

Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019;381(7):626–36. https://doi.org/10.1056/NEJMoa1904059.CrossRefPubMed

Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, et al. The mitogen-activated protein kinase pathway in melanoma part I—activation and primary resistance mechanisms to BRAF inhibition. Eur J Cancer. 2017;73:85–92. https://doi.org/10.1016/j.ejca.2016.12.010.CrossRefPubMed

Amaral T, Sinnberg T, Meier F, Krepler C, Levesque M, Niessner H, et al. MAPK pathway in melanoma part II—secondary and adaptive resistance mechanisms to BRAF inhibition. Eur J Cancer. 2017;73:93–101. https://doi.org/10.1016/j.ejca.2016.12.012.CrossRefPubMed

Yu Q, Xie J, Li J, Lu Y, Liao L. Clinical outcomes of BRAF plus MEK inhibition in melanoma: a meta-analysis and systematic review. Cancer Med. 2019;8(12):5414–24. https://doi.org/10.1002/cam4.2248.CrossRefPubMedPubMedCentral

Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014;4(1):80–93. https://doi.org/10.1158/2159-8290.CD-13-0642.CrossRefPubMed

Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877–88. https://doi.org/10.1056/NEJMoa1406037.CrossRefPubMed

10.

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30–9. https://doi.org/10.1056/NEJMoa1412690.CrossRefPubMed

11.

Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867–76. https://doi.org/10.1056/NEJMoa1408868.CrossRefPubMed

12.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):603–15. https://doi.org/10.1016/S1470-2045(18)30142-6.CrossRefPubMed

13.

Ascierto PA, McArthur GA, Dreno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17(9):1248–60. https://doi.org/10.1016/S1470-2045(16)30122-X.CrossRefPubMed

14.

Hauschild A, Larkin J, Ribas A, Dreno B, Flaherty KT, Ascierto PA, et al. Modeled prognostic subgroups for survival and treatment outcomes in BRAF V600-mutated metastatic melanoma: pooled analysis of 4 randomized clinical trials. JAMA Oncol. 2018;4(10):1382–8. https://doi.org/10.1001/jamaoncol.2018.2668.CrossRefPubMedPubMedCentral

15.

Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(10):1315–27. https://doi.org/10.1016/S1470-2045(18)30497-2.CrossRefPubMed

16.

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582–8. https://doi.org/10.1093/annonc/mdz011.CrossRefPubMedPubMedCentral

17.

Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20(9):1239–51. https://doi.org/10.1016/S1470-2045(19)30388-2.CrossRefPubMed

18.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019. https://doi.org/10.1056/NEJMoa1910836.CrossRefPubMedPubMedCentral

19.

Larkin J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller WH Jr, et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol. 2018;36(4):383–90. https://doi.org/10.1200/JCO.2016.71.8023.CrossRefPubMed

20.

Dickson PV, Gershenwald JE. Staging and prognosis of cutaneous melanoma. Surg Oncol Clin N Am. 2011;20(1):1–17. https://doi.org/10.1016/j.soc.2010.09.007.CrossRefPubMedPubMedCentral

21.

Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472–92. https://doi.org/10.3322/caac.21409.CrossRefPubMedPubMedCentral

22.

Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol. 2012;30(4):419–25. https://doi.org/10.1200/JCO.2011.38.0527.CrossRefPubMed

23.

Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18(7):863–73. https://doi.org/10.1016/S1470-2045(17)30429-1.CrossRefPubMedPubMedCentral

24.

Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19(5):672–81. https://doi.org/10.1016/S1470-2045(18)30139-6.CrossRefPubMed

25.

Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379(8):722–30. https://doi.org/10.1056/NEJMoa1805453.CrossRefPubMed

26.

Lewis KD, Larkin J, Ribas A, Flaherty KT, McArthur GA, Ascierto PA, et al. Impact of depth of response on survival in patients treated with cobimetinib +/− vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. Br J Cancer. 2019;121(7):522–8. https://doi.org/10.1038/s41416-019-0546-y.CrossRefPubMedPubMedCentral

27.

Menzer C, Menzies AM, Carlino MS, Reijers I, Groen EJ, Eigentler T, et al. Targeted therapy in advanced melanoma with rare BRAF mutations. J Clin Oncol. 2019;37(33):3142–51. https://doi.org/10.1200/JCO.19.00489.CrossRefPubMed

28.

Wang J, Chen J, Miller DD, Li W. Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma. Mol Cancer Ther. 2014;13(1):16–26. https://doi.org/10.1158/1535-7163.MCT-13-0212.CrossRefPubMed

29.

Shaffer SM, Dunagin MC, Torborg SR, Torre EA, Emert B, Krepler C, et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature. 2017;546(7658):431–5. https://doi.org/10.1038/nature22794.CrossRefPubMedPubMedCentral

30.

Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973–7. https://doi.org/10.1038/nature09626.CrossRefPubMedPubMedCentral

31.

Yadav V, Zhang X, Liu J, Estrem S, Li S, Gong XQ, et al. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem. 2012;287(33):28087–988. https://doi.org/10.1074/jbc.M112.377218.CrossRefPubMedPubMedCentral

32.

Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480(7377):387–90. https://doi.org/10.1038/nature10662.CrossRefPubMedPubMedCentral

33.

Choi J, Landrette SF, Wang T, Evans P, Bacchiocchi A, Bjornson R, et al. Identification of PLX4032-resistance mechanisms and implications for novel RAF inhibitors. Pigment Cell Melanoma Res. 2014;27(2):253–62. https://doi.org/10.1111/pcmr.12197.CrossRefPubMed

34.

Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, et al. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One. 2011;6(12):e28973. https://doi.org/10.1371/journal.pone.0028973.CrossRefPubMedPubMedCentral

35.

Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011;71(7):2750–60. https://doi.org/10.1158/0008-5472.CAN-10-2954.CrossRefPubMedPubMedCentral

36.

Hugo W, Shi H, Sun L, Piva M, Song C, Kong X, et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell. 2015;162(6):1271–85. https://doi.org/10.1016/j.cell.2015.07.061.CrossRefPubMedPubMedCentral

37.

Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35–44. https://doi.org/10.1016/j.cell.2016.02.065.CrossRefPubMedPubMedCentral

38.

Kreft S, Gesierich A, Eigentler T, Franklin C, Valpione S, Ugurel S, et al. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma. Eur J Cancer. 2019;116:207–15. https://doi.org/10.1016/j.ejca.2019.05.015.CrossRefPubMed

39.

Mason R, Dearden HC, Nguyen B, Oon JS, Smith JL, Randhawa M, et al. Combined ipilimumab and nivolumab first-line and after BRAF targeted therapy in advanced melanoma. Pigment Cell Melanoma Res. 2020;33(2):358–65. https://doi.org/10.1111/pcmr.12831.CrossRefPubMed

40.

Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer. 2014;120(11):1695–701. https://doi.org/10.1002/cncr.28620.CrossRefPubMed

41.

Czarnecka AM, Teterycz P, Mariuk-Jarema A, Lugowska I, Rogala P, Dudzisz-Sledz M, et al. Treatment sequencing and clinical outcomes in BRAF-positive and BRAF-negative unresectable and metastatic melanoma patients treated with new systemic therapies in routine practice. Target Oncol. 2019;14(6):729–42. https://doi.org/10.1007/s11523-019-00688-8.CrossRefPubMed

42.

Shin DS, Zaretsky JM, Escuin-Ordinas H, Garcia-Diaz A, Hu-Lieskovan S, Kalbasi A, et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 2017;7(2):188–201. https://doi.org/10.1158/2159-8290.CD-16-1223.CrossRefPubMed

43.

Sucker A, Zhao F, Pieper N, Heeke C, Maltaner R, Stadtler N, et al. Acquired IFNgamma resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. Nat Commun. 2017;8:15440. https://doi.org/10.1038/ncomms15440.CrossRefPubMedPubMedCentral

44.

Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8(1):1136. https://doi.org/10.1038/s41467-017-01062-w.CrossRefPubMedPubMedCentral

45.

Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Amon L, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019;25(12):1916–27. https://doi.org/10.1038/s41591-019-0654-5.CrossRefPubMedPubMedCentral

46.

Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, et al. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. Eur J Cancer. 2017;75:47–55. https://doi.org/10.1016/j.ejca.2017.01.009.CrossRefPubMed

47.

Shukla SA, Bachireddy P, Schilling B, Galonska C, Zhan Q, Bango C, et al. Cancer-germline antigen expression discriminates Clinical outcome to CTLA-4 blockade. Cell. 2018;173(3):624–33. https://doi.org/10.1016/j.cell.2018.03.026(e8).CrossRefPubMedPubMedCentral

48.

Saab KR, Mooradian MJ, Wang DY, Chon J, Xia CY, Bialczak A, et al. Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy. Cancer. 2019;125(6):884–91. https://doi.org/10.1002/cncr.31889.CrossRefPubMed

49.

Carlino MS, Vanella V, Girgis C, Giannarelli D, Guminski A, Festino L, et al. Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series. Br J Cancer. 2016;115(11):1280–4. https://doi.org/10.1038/bjc.2016.321.CrossRefPubMedPubMedCentral

50.

Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J Clin Oncol. 2018;36(17):1668–744. https://doi.org/10.1200/JCO.2017.75.6270.CrossRefPubMed

51.

Hauschild A, Dummer R, Schadendorf D, Santinami M, Atkinson V, Mandala M, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma. J Clin Oncol. 2018;36(35):JCO1801219. https://doi.org/10.1200/JCO.18.01219.CrossRef

52.

Atkins MB, Tarhini A, Rael M, Gupte-Singh K, O'Brien E, Ritchings C, et al. Comparative efficacy of combination immunotherapy and targeted therapy in the treatment of BRAF-mutant advanced melanoma: a matching-adjusted indirect comparison. Immunotherapy. 2019;11(7):617–29. https://doi.org/10.2217/imt-2018-0208.CrossRefPubMed

53.

Schilling B, Martens A, Geukes Foppen MH, Gebhardt C, Hassel JC, Rozeman EA, et al. First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis. Cancer Immunol Immunother. 2019;68(5):765–72. https://doi.org/10.1007/s00262-019-02311-1.CrossRefPubMed

54.

Moser JC, Chen D, Hu-Lieskovan S, Grossmann KF, Patel S, Colonna SV, et al. Real-world survival of patients with advanced BRAF V600 mutated melanoma treated with front-line BRAF/MEK inhibitors, anti-PD-1 antibodies, or nivolumab/ipilimumab. Cancer Med. 2019;8(18):7637–43. https://doi.org/10.1002/cam4.2625.CrossRefPubMedPubMedCentral

55.

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345–56. https://doi.org/10.1056/NEJMoa1709684.CrossRefPubMedPubMedCentral

56.

Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444–51. https://doi.org/10.1016/S0140-6736(15)60898-4.CrossRefPubMed

57.

Malkhasyan KA, Zakharia Y, Milhem M. Quality-of-life outcomes in patients with advanced melanoma: a review of the literature. Pigment Cell Melanoma Res. 2017;30(6):511–20. https://doi.org/10.1111/pcmr.12647.CrossRefPubMed

58.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. https://doi.org/10.1056/NEJMoa1504030.CrossRefPubMedPubMedCentral

59.

Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, et al. Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial. JAMA Oncol. 2019;5(2):187–94. https://doi.org/10.1001/jamaoncol.2018.4514.CrossRefPubMed

60.

Carlino MS, Long GV, Schadendorf D, Robert C, Ribas A, Richtig E, et al. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: a randomised clinical trial. Eur J Cancer. 2018;101:236–43. https://doi.org/10.1016/j.ejca.2018.06.034.CrossRefPubMed

Title: Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?
Authors: Patrick Schummer
Bastian Schilling
Anja Gesierich
Publication date: 01-08-2020
Publisher: Springer International Publishing
Keywords: Melanoma
Melanoma
Targeted Therapy
Published in: American Journal of Clinical Dermatology / Issue 4/2020
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI: https://doi.org/10.1007/s40257-020-00509-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2020

Dermatologists’ Role in the Diagnosis and Management of Coronavirus Disease 2019 Coagulopathy

Treatment Goals in Psoriasis: Which Outcomes Matter Most?

Eosinophilic Dermatoses: Recognition and Management

Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

Fabric Selection in Atopic Dermatitis: An Evidence-Based Review

New and Emerging Biologics for Atopic Dermatitis